These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 36169759)
1. Matrix metalloproteinase 1 is a poor prognostic biomarker for patients with hepatocellular carcinoma. Xu L; Yang H; Yan M; Li W Clin Exp Med; 2023 Oct; 23(6):2065-2083. PubMed ID: 36169759 [TBL] [Abstract][Full Text] [Related]
2. Identification of the MMP family as therapeutic targets and prognostic biomarkers in the microenvironment of head and neck squamous cell carcinoma. Liu M; Huang L; Liu Y; Yang S; Rao Y; Chen X; Nie M; Liu X J Transl Med; 2023 Mar; 21(1):208. PubMed ID: 36941602 [TBL] [Abstract][Full Text] [Related]
3. Landscape Analysis of Matrix Metalloproteinases Unveils Key Prognostic Markers for Patients With Breast Cancer. Cheng T; Chen P; Chen J; Deng Y; Huang C Front Genet; 2021; 12():809600. PubMed ID: 35069702 [TBL] [Abstract][Full Text] [Related]
4. Comprehensive bioinformatic analysis of MMP1 in hepatocellular carcinoma and establishment of relevant prognostic model. Dai L; Mugaanyi J; Cai X; Dong M; Lu C; Lu C Sci Rep; 2022 Aug; 12(1):13639. PubMed ID: 35948625 [TBL] [Abstract][Full Text] [Related]
5. MMP1 and MMP9 are potential prognostic biomarkers and targets for uveal melanoma. Wang T; Zhang Y; Bai J; Xue Y; Peng Q BMC Cancer; 2021 Sep; 21(1):1068. PubMed ID: 34587931 [TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase gene mutations and bioinformatics of telocytes in hepatocellular carcinoma. Luan C; Xu Y Cell Biol Int; 2023 Jan; 47(1):110-122. PubMed ID: 36273423 [TBL] [Abstract][Full Text] [Related]
7. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma. Bhuvarahamurthy V; Kristiansen GO; Johannsen M; Loening SA; Schnorr D; Jung K; Staack A Oncol Rep; 2006 May; 15(5):1379-84. PubMed ID: 16596214 [TBL] [Abstract][Full Text] [Related]
8. The Contribution of Matrix Metalloproteinase-1 Genotypes to Hepatocellular Carcinoma Susceptibility in Taiwan. Lai YL; Gong CL; Fu CK; Yueh TC; Tsai CW; Chang WS; Hsiao CL; Yen ST; Li HT; Jeng LB; Wang SC; Bau DT Cancer Genomics Proteomics; 2017; 14(2):119-125. PubMed ID: 28387651 [TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase 12 (MMP12) as an adverse prognostic biomarker of vascular invasion in hepatic cell carcinoma. Guo ZY; Jiang LP Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2238-2249. PubMed ID: 35442508 [TBL] [Abstract][Full Text] [Related]
10. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma. Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633 [TBL] [Abstract][Full Text] [Related]
11. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas]. Wei QY; Wu YQ; Fan SQ Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069 [TBL] [Abstract][Full Text] [Related]
12. The matrix metalloproteinase gene family: a significant prognostic gene lineage correlated with immune infiltrates in laryngeal squamous cell carcinoma. Yang C; Cao H; Yang JW; Liu T; Wang JT; Wang BS Neoplasma; 2021 Nov; 68(6):1212-1224. PubMed ID: 34585589 [TBL] [Abstract][Full Text] [Related]
13. A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential. Gobin E; Bagwell K; Wagner J; Mysona D; Sandirasegarane S; Smith N; Bai S; Sharma A; Schleifer R; She JX BMC Cancer; 2019 Jun; 19(1):581. PubMed ID: 31200666 [TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. Bradbury PA; Zhai R; Hopkins J; Kulke MH; Heist RS; Singh S; Zhou W; Ma C; Xu W; Asomaning K; Ter-Minassian M; Wang Z; Su L; Christiani DC; Liu G Carcinogenesis; 2009 May; 30(5):793-8. PubMed ID: 19321798 [TBL] [Abstract][Full Text] [Related]
16. An MMP-based risk score strongly distinguishes prognosis in hepatocellular carcinoma after resection. Jin Y; Liang ZY; Zhou WX; Zhou L Future Oncol; 2022 Aug; 18(26):2903-2917. PubMed ID: 35861053 [TBL] [Abstract][Full Text] [Related]
17. A novel prognostic models for identifying the risk of hepatocellular carcinoma based on epithelial-mesenchymal transition-associated genes. Xiong C; Wang G; Bai D Bioengineered; 2020 Dec; 11(1):1034-1046. PubMed ID: 32951492 [TBL] [Abstract][Full Text] [Related]
18. Identification of Rad51 as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma. Xu H; Xiong C; Chen Y; Zhang C; Bai D Bioengineered; 2021 Dec; 12(1):2664-2675. PubMed ID: 34115569 [TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase gene polymorphisms in chronic periodontitis: a case-control study in the Indian population. Majumder P; Ghosh S; Dey SK J Genet; 2019 Mar; 98():. PubMed ID: 30945680 [TBL] [Abstract][Full Text] [Related]
20. Macrophage-induced expression and release of matrix metalloproteinase 1 and 3 by human preadipocytes is mediated by IL-1β via activation of MAPK signaling. Gao D; Bing C J Cell Physiol; 2011 Nov; 226(11):2869-80. PubMed ID: 21935932 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]